Inhibitors of bruton's tyrosine kinase
US10093657B2 · kind B2 · utility
0Cited by
1References
2Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 9, 2017 |
| Grant date | Oct 9, 2018 |
| Priority date | — |
| Expiry date | Mar 9, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D409/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.